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Background: Pulmonary exacerbations (PEx) are critical events in cystic fibrosis (CF), responsible for reduced quality
of life and permanent loss of lung function. Approximately 1/4 of PEx are associated with failure to recover lung
function and/or resolve symptoms. Developing tools to optimize PEx treatment is of paramount importance.
Methods: We retrospectively audited all adults infected with Pseudomonas aeruginosa, experiencing PEx
necessitating parenteral antibiotic therapy from 2006–2012 from our center. Quantitative analysis of sputum at
admission, twice-weekly during hospitalization, and end of therapy were compared to baseline (most recent
healthy) and follow-up (after PEx) samples. Change in P. aeruginosa burden from baseline was assessed for any and
all morphotypes (ALL), as well as mucoid (MUC) and non-mucoid (NON) isolates specifically. PEx were identified as
failures if >90% of baseline pulmonary function was not recovered.
Results: Forty-six patients meeting the above inclusion and exclusion criteria experienced 144 PEx during this time
(median 3, IQR 2–6). Patients were treated for a median 14 days (IQR 13–16). No increase in ALL, MUC or NON were
detected at PEx, nor was there an association between change in sputum density and magnitude of lung function
decline. PEx failures were observed in 30% of events. Reductions of at least 1-log and 2 log P. aeruginosa sputum
density was observed in 57% and 46% (ALL), 73% and 55% (MUC) and 58% and 46% (NON) of PEx, respectively.
Factors associated with greater reduction of P. aeruginosa sputum density included choice of β-lactam antibiotic,
antibiotics with in vitro predicted activity and treatment duration. PEx associated with reductions in P. aeruginosa
sputum density were not associated with a reduced risk of PEx failure.
Conclusions: Enhanced killing of P. aeruginosa during PEx does not predict improved clinical outcomes. Studies
accounting for the polymicrobial nature of CF respiratory disease and the heterogeneity of P. aeruginosa causing
chronic infection may enable the identification of a more appropriate pathogen(s) based biomarker of PEx
outcomes.
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The archetypal CF pathogen, Pseudomonas aeruginosa
infects 50-70% of patients [1]. Patients with chronic P.
aeruginosa infection have increased rates of lung function
decline, health care utilization, and reduced survival [2-4].
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stated.acute deteriorations termed pulmonary exacerbations
(PEx). PEx are characterized by increased cough and spu-
tum production, disproportionate shortness of breath and
loss of lung function, as well as increased inflammation
[5-7]. PEx are critical events in CF, associated with re-
duced quality of life [8], increased cost [9], permanent
lung damage [10,11] and increased short-term mortality
[12,13]. So important are these events, they may now con-
stitute primary end-points in CF therapeutic trials [14].
Treatment of PEx usually consists of aggressive airway
clearance, respite, nutritional support, and antimicrobialis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
inal work is properly credited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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Despite therapy, 25% of PEx fail to achieve successful
outcomes as determined by lung function recovery,
resolution of symptoms and preventing recurrences [15].
Patients more likely to experience unsuccessful PEx out-
comes are infected with MRSA, Burkholderia cepacia
complex, MDR (multi-drug resistant) P. aeruginosa, and
those with CF-related diabetes and/or CF-liver disease
[10,15]. Furthermore, more severe PEx including those
with greater initial lung function decline, and those with
greater inflammation at initiation and completion of
treatment are associated with worse outcomes.
Developing tools to predict PEx outcomes is key to
their successful management. It has been previously
determined that antibiogram directed therapy against a
limited number of isolates of P. aeruginosa has only a
weak association with PEx outcomes [15]. As such, other
biomarkers are increasingly being evaluated for their
ability to predict treatment responses. A number of host
specific factors are being assessed [16,17]. However,
given the critical intervention in PEx is anti-bacterial,
the use of bacterial derived biomarkers to follow treat-
ment response deserves attention. While antibacterials
have been shown to reduce the bacterial load during the
treatment of PEx, how this correlates with clinical re-
sponse has not been established [18]. Herein we evaluate
the use of semi-quantitative reporting of P. aeruginosa
sputum density and correlated the response with clinical
outcomes during PEx treatment.
Methods
All CF patients chronically infected with P. aeruginosa
attending the Calgary Adult CF Clinic from 2006–2012
experiencing PEx treated with parenteral antibiotics were
considered for inclusion if they had semi-quantitative
sputum cultures performed ≥3 times during treatment
(baseline, initiation, early, end of therapy) and at follow-
up. Parenteral antibiotics provided for reasons other than
PEx were excluded. Patients were excluded if they had
a baseline FEV1 < 30% predicted, were infected with
Burkholderia cenocepacia or Mycobacterium abscessus, or
were listed for lung transplantation. Detailed review of
clinical records were performed from prior to the PEx,
through treatment and in follow-up. Pulmonary function
was evaluated by spirometry. Data was prospectively
collected and retrospectively analyzed. Patients provide
prospective consent for studies correlating clinical out-
comes with lower airways infection. This project has been
approved by the Conjoint Health Research Ethics Board of
the University of Calgary (E23087).
Definitions
Baseline lung function was defined as the best forced
expiratory volume in one second (FEV1) percent predictedin the preceding 6 months. The Leeds criteria was used to
define chronic P. aeruginosa infection [19]. PEx were diag-
nosed on clinical grounds in real time, however, charts
were evaluated and scored according to Fuchs criteria
retrospectively [5]. Parenteral therapies were provided as
either an inpatient, outpatient via the home parenteral
therapy program (HPTP) or a combination thereof.
Treatment failures were defined a priori as failure to
have recovered 90% of baseline FEV1 at follow-up
(FTR90) [10,11,15]. Severity of lung disease was catego-
rized as mild (FEV1% predicted ≥70%), moderate (40-70%),
and severe (<40%). Bacterial sputum density is reported
as log10 CFU/ml. Bacteriologic responses to anti-
pseudomonal therapies were evaluated as either a one
or two-log drop in CFU/ml.
Antibacterial therapies
Anti-Pseudomonal β-lactams (aztreonam, ceftazidime,
cefepime, and meropenem) were dosed 2 g every 8 hours
infused over thirty minutes, ciprofloxacin as 600 mg IV
or 750 mg PO every 12 hours, and tobramycin as
10 mg/kg/day divided in 1–2 doses. When patients with
chronic Staphylococcus aureus co-infection were treated
with regimens lacking Staphylococcal activity such as az-
treonam/ceftazidime, supplemental anti-Staphylococcal
therapies were used and consisted of trimethoprim/
sulfamethoxazole (TMP/SMX) 320/1600 mg PO BID,
linezolid 600 mg PO BID, rifampin 300 mg PO BID, or
cloxacillin 2 g IV q4h, clindamycin 600 mg IV q8h,
ceftriaxone 2 g IV q12h or tigecycline 50 mg q12h.
Microbiologic investigations
Baseline sputum samples were from the most recent
clinic where patients were not experiencing PEx. Twice-
weekly sputum samples were collected through treat-
ment. Admission samples were collected before starting
therapy. Changes in bacterial load were evaluated at
“EARLY” (3+/−2 days from starting) and “END” (within
3 days of completion). Follow-up samples were collected
at the next clinic visit attended.
Sputum samples were mixed with equal volumes of
dithiothreitol (DTT, Sputolysin, EMD Millipore, MA) and
vortexed. Samples were serial diluted in DTT to 10−5 and
plated on Columbia Blood Agar (CBA), MacConkey Agar,
(MAC), Chocolate Agar (CHOC), Burkholderia cepacia
selective agar, and Mannitol Salt Agar. Pathogens were
identified by standard criteria [20]. Oral flora (OF) in-
cluded organisms such as non-hemolytic Streptococci,
Haemophilus parainfluenzae, Corynebacterium spp.,
Neisseria spp. (non-meningitidis) and Coagulase-negative
Staphylococci grown on CBA or CHOC. Organisms were
quantified and P. aeruginosa colonies classified as mucoid
(MUC) or non-mucoid (NON) isolates based on growth
on MAC [21]. P. aeruginosa susceptibility testing was
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as per CLSI guidelines [22]. Where >1 MUC/NON iso-
lates existed susceptibility testing was performed on
each, and the result represents the least susceptible.
MDR was defined as resistance to all antibiotics in ≥2
classes and pan-drug resistance (PDR) all classes, save
for colistin [15,23].
Statistical analysis
Means with standard deviation (SD) or medians with
inter-quartile ranges (IQR) were used to describe normal
and non-normally distributed data, respectively. Categor-
ical variables were compared using a two-sided Fisher’s
exact test. Odds ratios (OR) were calculated by dividing
the proportion with a factor to those without and were re-
ported with 95% confidence intervals (CI). Continuous
variables were compared using Pearsons correlation coeffi-
cient. Statistical analyses were performed using Stata 12.0
(Stata Corp., College Station, TX, USA). A p value of
≤0.05 was considered significant.
Results
Patients and PEx
Of a total eligible cohort of 176, 46 patients met inclu-
sion criteria. These 46 patients experienced 144 PEx
during the six-year study period. Median age of those in-
cluded was 32.9 years (IQR 27.9-40). Patients were diag-
nosed with CF at a median age of 1.35 years (IQR 0.5-6).
56% were F508del homozygous and 83% carried ≥1
allele. 43 patients (93%) were pancreatic insufficient.
Co-morbidities included CF-related diabetes in 18 (40%),
CF-liver disease 8 (18%), osteopenia 60% and osteo-
porosis 9%. During the six years of study, 14 patients
initially included had future events excluded because of
progression of disease and three patients died, although
none from CF.
Patients experienced a median 3 exacerbations (IQR
2–6). Time to next PEx was 207 days (IQR 93–458).
Complete details were not available for all. Using Fuchs
criteria to confirm the clinical diagnosis of PEx, patients
had a median of 5 criteria (IQR 5–7), where 4 meet the
definition. The most common criteria were increased
cough (99%) and sputum (99%), increased dyspnea (98%),
decreased FEV1 by ≥10% (94%), weight loss or anorexia
(77%), change in chest exam (72%), radiographic infiltrates
(52%), lethargy (46%), fevers (37%), and hemoptysis (36%).
Sinus/nasal discharge symptoms were uncommonly docu-
mented (2%). At the time of exacerbation, chronic medica-
tions included: azithromycin 56%, H2-blockers or proton-
pump inhibitors 37%, inhaled corticosteroids (ICS) 54%,
long acting bronchodilators 85%, nebulized DNase 66%,
tobramycin inhalation solution 54%, and aztreonam
solution for inhalation 4%. With the exception of in-
haled antibiotics, chronic medications were continuedduring PEx. 70 (48%) of events were exclusively managed
in hospital, 42 (29%) were treated with HPTP, 32 (22%)
started off in hospital but completed at home, and two
(1%) were admitted to hospital from HPTP. Exacerbations
were associated with a median 19.3% (IRQ 11–28.5) and
18.2% (9.9-29) drop in FEV1 and FVC respectively.
Patients were treated for a median 14 days (IQR 13–16).
Two anti-pseudomonal antibiotics were used in 98% of
exacerbations, and three in 2%. These generally consisted
of an anti-pseudomonal β-lactam and tobramycin (96%).
Ceftazidime was used in 51%, meropenem 24%, cefepime
16%, and aztreonam 7%. Rarely ciprofloxacin was com-
bined with tobramycin (2%). Tobramycin was used in
once (14%) or twice-daily doses (81%), and parenteral
ciprofloxacin was used in place of tobramycin in five (3%)
exacerbations. Additional anti-Staphylococcal therapy was
used in 37 (26%) PEx and consisted of TMP/SMX (38%),
cloxacillin and TMP/SMX (19%), cloxacillin and rifampin
(14%), cloxacillin (11%) and rifampin, clindamycin,
clindamycin and ceftriaxone, tigecycline and linezolid
each in 3%.
Patients presented with an exacerbation 68 days (IQR
32–111) after their most recent clinic visit. Mean duration
from initiation of antibiotics to collection of EARLY spu-
tum culture was 3.84 days (SD 1.75). Mean duration from
the end of therapy to collection of END sputum sample
was 0.72 days (SD 1.70). 40 days (IQR 27–61) after com-
pletion of PEx treatment, patients were seen in follow-up
at a regular CF clinic.
PEx outcomes
PEx treatment failures, as defined by failing to recover 90%
of baseline FEV1, were observed in 42/140 (30%). Neither
sign, symptom, nor total Fuchs’ initial PEx diagnostic score
were associated with increased failure risk (not shown).
Stage of CF-lung disease did not influence failure (not
shown). Antibiotic courses ≤10 days were more likely to be
deemed failures; 8/16 (50%) vs 38/128 (30%), OR 1.68 (0.97-
2.94), p = 0.15) but this did not reach statistical significance.
Few prior and concomitant medications influenced PEx out-
comes. In particular, prior tobramycin inhalation solution
was associated with a trend to reduced risk of failure [17/74
vs 24/63 OR 0.6 (CI 0.36-1.01), p = 0.06] whereas conco-
mitant ICS were associated with a trend to increased risk
[27/42 vs 47/97, OR 1.33 (CI 0.98-1.80), p = 0.09] of failure.
Antibiotic choice did not impact PEx outcome, nor did the
number of antibiotics with in vitro predicted activity against
ALL, MUC or NON (not shown). Failure risk did not differ
based on delivery of PEx treatment; 33/68 (49%) in hospital,
18/42 (43%) HPTP, 9/32 (28%) transitioned from hospital to
HPTP, 1/2 (50%) admitted to hospital from HPTP, p = 0.24.
Concurrent use of additional anti-staphylococcal agents did
not reduce failure risk [11/30 (36%) vs 31/110 (28%), OR
1.32 (CI 0.75-2.31), p = 0.37].
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Median sputum density of OF at PEx was 106 CFU/ml
(IQR 105-106), S. aureus 106 (IQR 105-106), P. aerugi-
nosa ALL 106 (IQR 106-107), MUC 106 (IQR 105-106)
and NON 106 (IQR 105-107). Relative to baseline, admis-
sion PEx samples did not demonstrate an increase in
P. aeruginosa burden (Figure 1A). Furthermore, there
was no correlation between the extent of pulmonary
function decline at PEx presentation and change in bac-
terial load (not shown). Treatment produced a progres-
sive decline in P. aeruginosa in 60% of patients peaking
at end of therapy, but returned to baseline at follow-up
(Figure 1B-D). Stage of lung disease during PEx did not
influence bacteriologic response (not shown).
Clinical outcomes were not predicted based on changes
in sputum bacterial burden at completion of PEx treat-
ment (Table 1). Furthermore, outcomes were not different
in those few individuals who transiently cleared ALL,
MUC or NON (not shown).
In PEx where anti-pseudomonal β-lactams were used,
22.5% (32/142) of PEx had ≥1 isolate that was resistant.
At least one isolate was resistant to tobramycin, in 54.3%
(77/142) of PEx. Highly resistant isolates were rare in
admission PEx samples and over a one-year period prior
to PEx (MDR; MUC 6% (6/103), 22% (25/116); NON
41% (45/110), 50% (57/113) and PDR; MUC 1% (1/103),C D
BA
Figure 1 Change in P. aeruginosa CFU/ml during PEx. A). Change in CF
CFU at EARLY time point (~day 4) of antibiotic treatment relative to admission
admission. D). Change in CFU at follow-up clinic visit relative to admission. Bla
bars with black dots NON.3% (3/115) and NON 12% (13/109), 22% (25/113), re-
spectively. Antibiotic choice impacted P. aeruginosa
sputum reduction to varying degrees (Table 2, Figures 2
and 3). Relative to other antibiotics ceftazidime showed
a modest advantage, whereas cefepime was associated
with reduced P. aeruginosa killing. Tobramycin dosing
once or twice daily did not influence bacteriologic re-
sponse (data not shown). An association between number
of antibiotics with in vitro predicted activity and reduction
of P. aeruginosa density was observed although this
reached statistical significance only for regimens with ac-
tivity against the NON-isolates (Table 3).
No significant impact of concurrent therapies was
noted on reductions in P. aeruginosa sputum density. In
particular, concurrent chronic azithromycin, DNase, nor
hypertonic saline impacted P. aeruginosa density. A trend
was observed in individuals receiving concurrent ICS at
having a lower likelihood of reducing P. aeruginosa
sputum burden (not shown). Venue for antibiotic delivery
did not impact bacteriologic response (not shown). Treat-
ments <14 days produced an inferior bacteriologic re-
sponse, although this met statistical significance for only
the NON-isolates (Table 2).
MSSA was a chronic colonizer of patients in 31/146
(21.2%) of PEx, and two had a history of recent-prior
MRSA transient colonization, though none on admission.U from baseline sputum to admission at time of PEx. B). Change in
. C). Change in CFU at the END of antibiotic treatment for PEx relative to
ck bars represent all P. aeruginosa isolates, grey bars only MUC, and white
Table 1 Bacteriologic response does not predict clinical outcomes of pulmonary exacerbations
Organism Morph Log drop Failure risk*
Actual values** OR (CI) P value
P. aeruginosa ALL 1 26% (18/68) vs 33% (17/51) 0.78 (0.46-1.38) 0.42
2 27% (15/55) vs 31% (20/64) 0.87 (0.5-1.5) 0.68
MUC 1 28% (21/74) vs 23% (6/26) 1.22 (0.56-2.70) 0.79
2 30% (17/56) vs 22% (10/44) 1.36 (0.68-2.62) 0.49
NON 1 30% (19/64) vs 35% (16/46) 0.85 (0.49-1.47) 0.68
2 33% (17/51) vs 30% (18/59) 1.1 (0.63-1.88) 0.84
S. aureus 2 46% (12/26) vs 0% (0/3) n/a 0.25
4 31% (5/16) vs 54% (7/13) 0.58 (0.28-1.58) 0.27
Oral Flora 1 22% (13/60) vs 34% (23/67) 0.63 (0.35-1.13) 0.12
2 23% (9/39) vs 31% (27/88) 0.75 (0.39-1.44) 0.52
*Failure was defined as failing to achieve 90% of baseline percent predicted FEV1 at time of follow-up.
**Risk of failure to achieve outcome in those PEx achieving the log drop in bacterial counts relative to those events where a drop was not observed.
ALL = all P. aeruginosa morphotypes, MUC =mucoid, NON = non-mucoid isolates, OR = odds ration, CI = confidence intervals.
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riologic response with 26/30 (81%), 20/30 (67%), 14/30
(46%) experiencing at least a 2-log, 4-log or 6-log drop in
MSSA, respectively at the end of therapy. Bacteriologic
responses of MSSA and OF during PEx did not predict
clinical success (Table 1). During fourteen PEx, new path-
ogens were apparent during twice-weekly samples, dif-
ferent from admission. These included Aspergillus (4),
Stenotrophomonas maltophilia (4), Group C Streptococ-
cus (3), and one each of MSSA, MRSA and H. influenzae.
None of these resulted in changed antimicrobial manage-
ment (with the exception of TMP/SMX for MRSA) and
none manifested in chronic infection. Exacerbations asso-
ciated with the emergence of new pathogens did not im-
pact risk of PEx failure [5/42 (12%) vs 9/108 (8%), OR 1.41
(CI 0.5-3.98), p = 0.54].
Early bacteriologic response and correlation to end of
therapy
Change in CFU of P. aeruginosa EARLY into the anti-
bacterial treatment correlated with change in load by the
END of the treatment for ALL (Prob > F <0.0001, r2 =
0.27), MUC (Prob > F =0.0003, r2 = 0.189) and NON-
MUC (Prob > F <0.0001, r2 = 0.30) (Figure 4). EARLY
changes in bacterial load did not, however, predict fail-
ure risk for any P. aeruginosa morphotype (not shown).
Discussion
PEx are increasingly recognized as a significant contribu-
tor to the progressive nature of CF lung disease [24].
Avoiding PEx is critical in this regard, and many CF
therapies may exert their beneficial effects in manner
[5,25-27]. However, despite attempts to limit their occur-
rence, PEx remain common. Given that some PEx are
associated with worse outcomes than others, strategiesto identify and optimize the management of these events
are critical.
Anti-pseudomonal antibiotics are an integral compo-
nent of PEx management. Independent of enhanced air-
way clearance, anti-pseudomonal antibacterials have
been shown to improve pulmonary function in a linear
capacity relative to reducing P. aeruginosa burden [18].
Few studies however, have tried to identify factors asso-
ciated with enhanced P. aeruginosa killing. Smith et al.,
followed 75 patients chronically infected with P. aerugi-
nosa through PEx managed with single or dual agent
anti-pseudomonals [28]. While they observed a general
reduction in sputum density of P. aeruginosa, reduced
sputum DNA and protein levels, none of these factors
correlated with absolute change in pulmonary function.
Similarly, Mclaughlin et al., did not observe a correlation
between burden of P. aeruginosa and absolute lung func-
tion recovery [29]. More recently, Deschaght et al., per-
formed an observational study where they identified a
correlation between improvement in lung function and
reduction in P. aeruginosa density using quantitative
PCR [30]. These studies, however, focused on aggregate
analysis of lung function improvement and did not
categorize individual events on the basis of success or
failure, nor assess impact of individual morphotypes.
We sought to determine if bacteriologic killing as a
measure of effectiveness of antibacterial therapies corre-
lated with clinical outcomes in PEx. During antibacterial
treatment of PEx, a progressive decline in P. aeruginosa
burden was noted in approximately 60% of patients. This
decline was predictable based on early changes in P. aer-
uginosa burden after only four days of treatment. Reduc-
tion in total P. aeruginosa burden, nor mucoid or non-
mucoid isolates specifically did not, however, correlate
with risk of failing to recover lung function. Enhanced
Table 2 Treatment factors associated with reduced P. aeruginosa bacterial burden at END of PEx therapies
Factor ALL MUC NON
Value OR (95% CI) Value OR (95% CI) Value OR (95% CI) Value OR (95% CI) Value OR (95% CI) Value OR (95% CI)















































































*Other antibiotics including aztreonam, meropenem, ciprofloxacin and dosing of tobramycin did not show significance and have not been included.














Figure 2 Percentage of PEx achieving a 1 or 2-log reduction in P. aeruginosa sputum density at end of antibacterial therapy as a function
of the number of empirically provided antibiotics with in vitro predicted activity from admission sputum sample. A). Antibiotics with activity
against Mucoid isolates. B). Antibiotics with activity against Non-Mucoid isolates.
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ing antibacterials estimated to have more potent in vitro
activity. This was particularly true when antibiotics had
greater activity against non-mucoid isolates that were
more readily reduced with antibiotics. Furthermore, we
have observed like others, that in those few patients who
transiently achieve clearance of P. aeruginosa during
PEx treatments, no enhancement in clinical outcomes
was afforded [29].
To complicate matters, studies have shown resolution
of PEx in patients chronically infected with P. aeruginosa
treated with regimens devoid of anti-pseudomonal activityFigure 3 Percentage of PEx achieving a 1 or 2-log reduction in P. aer
function of the β-lactam antibiotic used.suggesting response is more complicated than a one-host
and one-pathogen model [31,32]. Accordingly, more re-
cent studies have assessed the impact of antibacterials
on other constituents of the CF respiratory microbiome,
beyond classical CF pathogens. Using enhanced culturing
to identify the Streptococcus milleri group (S. anginosus
group, SMG), 40% of PEx were identified to have this
organism emerge as numerically dominant at the onset of
PEx, and resolution of symptoms correlated with reduc-
tion in sputum burden [31,33,34]. Using culture independ-
ent techniques, others have observed that with the
exception of the Prevotella and Chrysiogenales, levels ofuginosa sputum density at end of antibacterial therapy as a
Table 3 Relation of in vitro predicted susceptibility to reduction in P. aeruginosa bacterial burden at END of PEx therapies
Factor ALL MUC NON
Value OR (95% CI) Value OR (95% CI) Value OR (95% CI) Value OR (95% CI) Value OR (95% CI) Value OR (95% CI)
1-log reduction 2-log reduction 1-log reduction 2-log reduction 1-log reduction 2-log reduction
All Isolates S to
β-lactam vs not
59/91 vs 8/27 2.18 (CI 1.2-3.99)
p = 0.002



















to TOB vs not
32/53 vs 35/65 1.12 (0.82-1.53),
p = 0.56


















Regimen with 2 vs
≤1 MUC agent*
47/73 vs 12/25 1.34 (0.87-2.08),
p = 0.16











Regimen with 2 vs
≤1 NON agent*
29/41 vs 33/67 1.43 (1.05-1.96),
p = 0.04




























MDR in prior year*
vs not
















PDR at PEx* vs not N/A N/A 0/1 vs
61/81
n/a p = 0.21 0/1 vs
46/79








PDR in prior year*
vs not
N/A N/A 0/1 vs
59/79
n/a p = 0.26 0/1 vs
46/79








*In these events, bacteriologic response of P. aeruginosa was evaluated specifically against the morphotype type that susceptibility was being evaluated.
S = sensitive as defined by CLSI criteria. TOB = tobramycin. MUC =mucoid isolate, NON = non-mucoid isolate. PEx = pulmonary exacerbation. OR = Odds ratio, CI = confidence interval. N/A = not applicable.
MDR/PDR at event = Presence of an MDR/PDR isolate at admission sputum sample of the PEx being evaluated.















Figure 4 Correlation in change in CFU from admission sputum
sample Early in to exacerbation therapy (Y axis) to End of
therapy (X axis). A). ALL P. aeruginosa morphotypes, B). Mucoid
only isolates, C). Non-mucoid Isolates.
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provements in lung function [35,36].
We did not detect an increase in either total P. aerugi-
nosa load, or specifically MUC or NON morphotypes
associated with an exacerbation. Nor was there an asso-
ciation between change in P. aeruginosa sputum density
and extent of decline in pulmonary function. This datamirrors that of other recent studies that have challenged
the long held belief that an increase in P. aeruginosa
triggers PEx [37-39]. Clearly, factors other than changes
in macroscopically apparent P. aeruginosa morphotypes are
involved. These factors may include: environmental expo-
sures such as pollution [40] and allergens [41]; host factors
such as medication compliance [42] and co-morbidities
[15,43,44] pathogen factors such as respiratory viruses [45],
changes in the constituents of the lower respiratory micro-
biome [33,46] and specific P. aeruginosa sub-populations
[47,48]. Furthermore, it is likely that there are multiple
convergent pathways leading to a PEx, and these events
vary in their manifestations and potential outcomes.
Many contentious issues exist in PEx management strat-
egies. Data in these areas are difficult to interpret as out-
comes have traditionally focused on absolute improvement
in pulmonary function, as opposed to a more appropriate
model of proportional recovery [46,47] Whereas some, but
not all studies have suggested HPTP to be inferior, we
noted similar outcomes in risk of failures and reductions in
P. aeruginosa burden [46,47]. Likewise length of therapy for
PEx has been debated [49]. Herein we noted a trend
towards increased risk of failure to recover lung function
with therapies ≤10 days, but no benefit with extending
therapies >14 days. We also observed treatments <14 days
were inferior in reducing P. aeruginosa sputum density.
The effectiveness of different antibiotics in achieving
good PEx outcomes has been previously assessed. Herein
we did observe differential abilities of antibiotics to reduce
P. aeruginosa burden. In particular, cefepime was inferior
at reducing P. aeruginosa sputum burden, although no im-
pact on PEx outcome was noted. Interestingly, meta-
analyses have demonstrated patients treated with cefepime
relative to an alternate β-lactam with a similar spectrum
of activity may be associated with an increased risk of
mortality [50,51]. While commonly used in CF, the only
clinical studies evaluating cefepime in CF have been phar-
macokinetic based [52,53]. Based on these data, further
studies of cefepime usage in CF are advisable.
ICS are common agents in CF, with approximately one
third of patients receiving them. However, their utility
has not clearly been established and the general consen-
sus is that they are over used and may even be harmful
[54]. Indeed, in a randomized controlled trial to evaluate
the effects of discontinuation of ICS in patients stably
maintained on ICS showed equivalent outcomes [55]. ICS
use has been associated with increased risk of PEx [43,56].
Our results now suggest an increased risk of PEx failure
with ICS use, a trend towards reduced sputum density
of P. aeruginosa during antibacterial treatment and may
warrant further caution with these agents in CF.
Herein we have attempted to expand upon other studies
assessing PEx outcomes and changes in P. aeruginosa spu-
tum density. To do so we have utilized a proportional lung
Lam et al. BMC Infectious Diseases  (2015) 15:145 Page 10 of 12function recovery model to overcome the deficiency
whereby other studies using absolute improvement fail to
account for the extent of initial decline and therefore are
poor predictors of success or failure [15]. While this work
relies on clinician diagnosed PEx events, we have retro-
spectively confirmed they met diagnostic criteria using an
established PEx diagnostic algorithm [5]. Furthermore, we
have attempted to evaluate outcomes based on individual
morphotypes of P. aeruginosa reported routinely by
clinical laboratories [20]. Indeed, quantitative analysis
of P. aeruginosa using qPCR would not distinguish be-
tween mucoid and non-mucoid isolates. As infection
with mucoid isolates of P. aeruginosa is associated with
reduced success of eradication treatment in patients
with new infection [57,58] and a worse prognosis for
patients with chronic lung infection [3,59], it might be
expected that a differential response against mucoid
isolates might impact PEx outcomes. This appears not
to be the case.
Several limitations of this work deserve consideration.
Because diagnosis of PEx were collected and analyzed
retrospectively, the data is not as robust as prospectively
collected data. Symptoms or signs not documented in
clinical records may inadvertently be documented as
absent. This may be somewhat mitigated, as these find-
ings were collected at a single CF clinic over a short time
period, where practice patterns were relatively uniform.
Our study excluded PEx not requiring parenteral anti-
biotics. We observed a significantly higher rate of PEx
failures than in other works [10,11,15]. While similar
criteria were used in the selection of only parenteral
antibiotic treated PEx, far fewer patients were treated
with parenteral antibiotics in this study. This likely re-
flects institutional practice variation in the management
of PEx and availability of local resources. Parenteral
antibiotics were reserved for the most severe events as
evidenced by the significant decline in lung function on
admission. This is further supported by the relatively low
level of P. aeruginosa drug resistance observed herein rela-
tive to other works [15,60]. Whether more aggressive
management of exacerbations would result in improved
outcomes is of interest.
Conclusions
In this work we identified that while the majority of pa-
tients treated with parenteral anti-pseudomonals expe-
rienced a temporary reduction in sputum burden,
approximately 40% did not. This bacteriologic response
could be predicted on the basis of sputum samples col-
lected early into antibiotic treatment. Antibacterial
treatments with a greater number of agents with in vitro
predicted activity against all morphotypes, and in parti-
cular non-mucoid isolates was more likely to result in
enhanced P. aeruginosa killing during PEx. However,patients who experienced enhanced killing of P. aerugi-
nosa after completion of therapy were not afforded a re-
duced risk of PEx failure. Accordingly, bacteriologic
response during PEx treatment cannot be used to pre-
dict success.
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